Breaking News, Collaborations & Alliances

Lilly, Aduro Biotech in Immunotherapy Alliance

Will use cGAS-STING Pathway Inhibitor program to develop immunotherapies for autoimmune and other inflammatory diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. and Aduro Biotech, Inc. have entered a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway Inhibitor program for the development of novel immunotherapies for autoimmune and other inflammatory diseases.   Aduro’s cGAS-STING Pathway Inhibitor program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which can modulate the immune response associated with various autoimmune di...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters